Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982038500> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W1982038500 endingPage "599" @default.
- W1982038500 startingPage "589" @default.
- W1982038500 abstract "Doxorubicin and daunorubicin, the anthracycline anti-tumor agents, were evaluated for their in vitro and in vivo effect on phosphodiesterase (PDE) activity in mouse tissues. Doxorubicin at a concentration of 10−4M inhibited cardiac c-AMP (adenosine 3′,5′, monophosphate) PDE activity 50% of the control whereas in lungs and spleen, the activity was inhibited only 20%. On the contrary no effect was seen in kidney and liver. In addition, cardiac c-GMP (quanosine 3′,5′ monophosphate) PDE appeared less sensitive to doxorubicin than c-AMP PDE though inhibition in heart was more pronounced than in any other tissue. It appears that daunorubicin inhibits c-AMP PDE activity in heart markedly less than doxorubicin. Kinetic studies indicate that both inhibitions of c-AMP and c-AMP PDE by doxorubicin were non-competitive with substrate. Intravneous administration of 20 and 30 mg/kg of free doxorubicin to CDF1 mice resulted in 33 and 39% decreases in cardiac c-AMP PDE activity respectively by 72 hrs. In contrast, similar intravenous injections of same doses of doxorubicin entrapped in cardiolipin liposomes had no effect on c-AMP PDE activity in any tissues. These studies demonstrate the relative selectivity of the cardiac cyclic nucleotide PDE inhibitory effect of doxorubicin suggesting that this inhibition might be one aspect of the mechanism of anthracycline-induced cardiotoxicity." @default.
- W1982038500 created "2016-06-24" @default.
- W1982038500 creator A5018146912 @default.
- W1982038500 creator A5052787538 @default.
- W1982038500 creator A5062682753 @default.
- W1982038500 creator A5074438095 @default.
- W1982038500 date "1985-02-01" @default.
- W1982038500 modified "2023-09-26" @default.
- W1982038500 title "Selective inhibition of cardiac cyclic nucleotide phosphodiesterases by doxorubicin and daunorubicin" @default.
- W1982038500 cites W1596658458 @default.
- W1982038500 cites W1775749144 @default.
- W1982038500 cites W1969262864 @default.
- W1982038500 cites W2012108926 @default.
- W1982038500 cites W2019122401 @default.
- W1982038500 cites W2041118633 @default.
- W1982038500 cites W2083670956 @default.
- W1982038500 doi "https://doi.org/10.1016/0024-3205(85)90641-1" @default.
- W1982038500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2982070" @default.
- W1982038500 hasPublicationYear "1985" @default.
- W1982038500 type Work @default.
- W1982038500 sameAs 1982038500 @default.
- W1982038500 citedByCount "5" @default.
- W1982038500 crossrefType "journal-article" @default.
- W1982038500 hasAuthorship W1982038500A5018146912 @default.
- W1982038500 hasAuthorship W1982038500A5052787538 @default.
- W1982038500 hasAuthorship W1982038500A5062682753 @default.
- W1982038500 hasAuthorship W1982038500A5074438095 @default.
- W1982038500 hasConcept C121608353 @default.
- W1982038500 hasConcept C126322002 @default.
- W1982038500 hasConcept C134018914 @default.
- W1982038500 hasConcept C150903083 @default.
- W1982038500 hasConcept C181199279 @default.
- W1982038500 hasConcept C185592680 @default.
- W1982038500 hasConcept C207001950 @default.
- W1982038500 hasConcept C2776694085 @default.
- W1982038500 hasConcept C2776802502 @default.
- W1982038500 hasConcept C2778233292 @default.
- W1982038500 hasConcept C2780215583 @default.
- W1982038500 hasConcept C2781021840 @default.
- W1982038500 hasConcept C2781303535 @default.
- W1982038500 hasConcept C29730261 @default.
- W1982038500 hasConcept C530470458 @default.
- W1982038500 hasConcept C55493867 @default.
- W1982038500 hasConcept C62826618 @default.
- W1982038500 hasConcept C71924100 @default.
- W1982038500 hasConcept C86803240 @default.
- W1982038500 hasConcept C98274493 @default.
- W1982038500 hasConceptScore W1982038500C121608353 @default.
- W1982038500 hasConceptScore W1982038500C126322002 @default.
- W1982038500 hasConceptScore W1982038500C134018914 @default.
- W1982038500 hasConceptScore W1982038500C150903083 @default.
- W1982038500 hasConceptScore W1982038500C181199279 @default.
- W1982038500 hasConceptScore W1982038500C185592680 @default.
- W1982038500 hasConceptScore W1982038500C207001950 @default.
- W1982038500 hasConceptScore W1982038500C2776694085 @default.
- W1982038500 hasConceptScore W1982038500C2776802502 @default.
- W1982038500 hasConceptScore W1982038500C2778233292 @default.
- W1982038500 hasConceptScore W1982038500C2780215583 @default.
- W1982038500 hasConceptScore W1982038500C2781021840 @default.
- W1982038500 hasConceptScore W1982038500C2781303535 @default.
- W1982038500 hasConceptScore W1982038500C29730261 @default.
- W1982038500 hasConceptScore W1982038500C530470458 @default.
- W1982038500 hasConceptScore W1982038500C55493867 @default.
- W1982038500 hasConceptScore W1982038500C62826618 @default.
- W1982038500 hasConceptScore W1982038500C71924100 @default.
- W1982038500 hasConceptScore W1982038500C86803240 @default.
- W1982038500 hasConceptScore W1982038500C98274493 @default.
- W1982038500 hasIssue "6" @default.
- W1982038500 hasLocation W19820385001 @default.
- W1982038500 hasLocation W19820385002 @default.
- W1982038500 hasOpenAccess W1982038500 @default.
- W1982038500 hasPrimaryLocation W19820385001 @default.
- W1982038500 hasRelatedWork W1966351170 @default.
- W1982038500 hasRelatedWork W1983071596 @default.
- W1982038500 hasRelatedWork W2035096408 @default.
- W1982038500 hasRelatedWork W2046079725 @default.
- W1982038500 hasRelatedWork W2145128878 @default.
- W1982038500 hasRelatedWork W2305100815 @default.
- W1982038500 hasRelatedWork W2594612537 @default.
- W1982038500 hasRelatedWork W2904179235 @default.
- W1982038500 hasRelatedWork W4237090850 @default.
- W1982038500 hasRelatedWork W3144870107 @default.
- W1982038500 hasVolume "36" @default.
- W1982038500 isParatext "false" @default.
- W1982038500 isRetracted "false" @default.
- W1982038500 magId "1982038500" @default.
- W1982038500 workType "article" @default.